Major Depressive Disorder Clinical Trial
Official title:
A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder
Verified date | February 2019 |
Source | Forest Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is an outpatient study to evaluate the safety, and efficacy of RGH-188 as an add-on therapy to standard antidepressants in patients who did not respond to previous antidepressant therapy.
Status | Completed |
Enrollment | 231 |
Est. completion date | December 6, 2010 |
Est. primary completion date | December 6, 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Men and women, 18-65 years old - Currently meet the DSM-IV-TR criteria for moderate to severe MDD without psychotic features. - Previous failure to respond to adequate trials of one or two ADTs with less than 50% reduction in depressive symptoms during the present episode. Exclusion Criteria: - DSM-IV-TR based diagnosis of an axis I disorder, other than MDD, or any axis I disorder other than MDD that was the primary focus of treatment within 6 months before Visit 1 |
Country | Name | City | State |
---|---|---|---|
United States | Forest Investigative Site | Arcadia | California |
United States | Forest Investigative Site 033 | Atlanta | Georgia |
United States | Forest Investigative Site | Bellevue | Washington |
United States | Forest Investigative Site 001 | Bronx | New York |
United States | Forest Investigative Site 043 | Brooklyn | New York |
United States | Forest Investigative Site | Canton | Ohio |
United States | Forest Investigative Site | Cherry Hill | New Jersey |
United States | Forest Investigative Site | Dayton | Ohio |
United States | Forest Investigative Site 025 | Denver | Colorado |
United States | Forest Investigative Site | Encino | California |
United States | Forest Investigative Site 042 | Fall River | Massachusetts |
United States | Forest Investigative Site | Garden Grove | California |
United States | Forest Investigative Site | Irvine | California |
United States | Forest Investigative Site 007 | Jacksonville | Florida |
United States | Forest Investigative Site 013 | Los Alamitos | California |
United States | Forest Investigative Site 006 | Media | Pennsylvania |
United States | Forest Investigative Site 023 | Memphis | Tennessee |
United States | Forest Investigative Site 031 | Memphis | Tennessee |
United States | Forest Investigative Site 020 | Mount Kisco | New York |
United States | Forest Investigative Site | Nashville | Tennessee |
United States | Forest Investigative Site 041 | National City | California |
United States | Forest Investigative Site 029 | New York | New York |
United States | Forest Investigative Site 039 | New York | New York |
United States | Forest Investigative Site | Norwich | Connecticut |
United States | Forest Investigative Site | Oceanside | California |
United States | Forest Investigative Site | Omaha | Nebraska |
United States | Forest Investigative Site | Overland Park | Kansas |
United States | Forest Investigative Site | Philadelphia | Pennsylvania |
United States | Forest Investigative Site | Philadelphia | Pennsylvania |
United States | Forest Investigative Site 040 | Phoenix | Arizona |
United States | Forest Investigative Site 034 | Pittsfield | Massachusetts |
United States | Forest Investigative Site 015 | Portland | Oregon |
United States | Forest Investigative Site 032 | Raleigh | North Carolina |
United States | Forest Investigative Site | Richmond | Virginia |
United States | Forest Investigative Site | Roswell | Georgia |
United States | Forest Investigative Site | San Antonio | Texas |
United States | Forest Investigative Site 038 | Scottsdale | Arizona |
United States | Forest Investigative Site | Seattle | Washington |
United States | Forest Investigative Site | Washington | District of Columbia |
United States | Forest Investigative Site 012 | West Palm Beach | Florida |
United States | Forest Investigative Site | Woodstock | Vermont |
Lead Sponsor | Collaborator |
---|---|
Forest Laboratories | Gedeon Richter Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Montgomery-Asberg Depression Rating Scale (MADRS) | The patient is rated on a scale from 0-6 on 10 items. Apparent sadness, reported sadness, lassitude, pessimistic thoughts, inner tension, suicidal thoughts, reduced sleep and appetite, concentration difficulties, inability to feel. The overall MADRS score ranges from 0-60, with 0 meaning no symptoms and score of 60 meaning maximum severity. The primary efficacy parameter was the change in MADRS score totals from the scores taken at Baseline (Week 8) and during at least one more time point up to and including Week 16. | Baseline (Week 8) to Week 16 | |
Secondary | Clinical Global Impression - Improvement (CGI-I) | The Clinical Global Impression-Improvement (CGI-I) scale is a clinician rated scale that, in this study, will be used to rate total improvement or worsening of mental illness starting at Visit 2 (Week 2) and taken at every visit through Visit 11 (Week 16). The patient will be rated on a scale from 1 to 7, 1 indicating that the patient is very much improved and 7 indicating that the patient is very much worse. The secondary efficacy parameter was the CGI-I total score at Week 16. | Week 16 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |